Stock comparison
Haemonetics
Krystal Biotech
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
KRYS
Krystal Biotech
Market cap
$8.83B
Sector
Healthcare
Overall winner
Krystal Biotech KRYS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | KRYS | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 51C | HAE |
| Benjamin Graham | 85A | 74D | HAE |
| Philip Fisher | 60C | 74C | KRYS |
| Peter Lynch | 54C | 58C | KRYS |
| Joel Greenblatt | 31F | 59C | KRYS |
| Charlie Munger | 54D | 64D | KRYS |
| Terry Smith | 55D | 64D | KRYS |
Side-by-side metrics
| Metric | HAE | KRYS |
|---|---|---|
| Market cap | $2.98B | $8.83B |
| P/E (TTM) | 24.8x | 39.9x |
| EV/EBIT | 14.1x | 52.9x |
| ROIC (TTM) | 8.37% | 13.85% |
| Gross margin | 55.74% | 92.79% |
| Net margin | 7.29% | 53.92% |
| Revenue CAGR 5y | 7.65% | - |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 52.9x+73%
- P/E (TTM)24.8xvs 39.9x+38%
KRYS leads on
- Debt / Equity0.0xvs 1.5x+100%
- Net margin53.92%vs 7.29%+86%
- Market cap$8.83Bvs $2.98B+66%
- Gross margin92.79%vs 55.74%+40%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.